search
Back to results

Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates (ATHLETE)

Primary Purpose

Benign Prostatic Hyperplasia (BPH)

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Aquablation
HoLEP
Sponsored by
Dr. med. Gautier Müllhaupt
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Benign Prostatic Hyperplasia (BPH)

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Men ≥45 years of age

    • Patient must be a candidate for HoLEP
    • Refractory to medical therapy or patient is not willing to consider (further) medical treatment
    • Patient has a prostate size of at least 50 ml and not more than 150ml, measured by transrectal ultrasound (TRUS)
    • IPSS ≥12
    • QoL≥3
    • Qmax ≤ 15 ml/s with a minimum voided volume ≥ 125 ml or patient in urinary retention
    • Written informed consent

Exclusion Criteria:

  • Neurogenic lower urinary tract dysfunction

    • Urethral stenosis
    • Preinterventionally proven adenocarcinoma of the prostate
    • Nickel allergy
    • Not able to complete questionnaires due to cognitive or thought disorders
    • Language skills insufficient for informed consent and / or completion of questionnaires

Sites / Locations

  • Cantonal Hospital St. GallenRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Aquablation

HoLEP

Arm Description

Outcomes

Primary Outcome Measures

International Prostate Symptoms Score (IPSS)
The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

Secondary Outcome Measures

Full Information

First Posted
September 14, 2020
Last Updated
January 7, 2021
Sponsor
Dr. med. Gautier Müllhaupt
search

1. Study Identification

Unique Protocol Identification Number
NCT04560907
Brief Title
Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates
Acronym
ATHLETE
Official Title
Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates: A Prospective Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 5, 2021 (Anticipated)
Primary Completion Date
April 2023 (Anticipated)
Study Completion Date
November 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr. med. Gautier Müllhaupt

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Benign prostatic hyperplasia (BPH) is one of the most common diseases in men. As BPH progresses, surgical treatments often become necessary. Holmium enucleation of the prostate (HoLEP) is an established procedure in the surgical treatment of BPH, especially for medium to large prostates. The long learning curve, the length of surgery, and expensive equipment still limit the availability of HoLEP to a few specialized centers. Recently, a new method for treating BPH called aquablation has become commercially available. This technique uses real-time ultrasound imaging in combination with a robotic high-pressure water jet programmed and guided by the surgeon to resect prostate tissue. A RCT has shown functional results similar to transurethral resection of the prostate (TURP) for small to medium size prostates . However, so far there are no controlled studies assessing whether Aquablation provides patient reported and functional outcomes that are non-inferior compared to HoLEP in medium size to large prostates (the latter cannot be operated by TURP due to its size limitations). As aquablation offers some obvious advantages compared to HoLEP regarding learning curve and operation time, the aim of this study is to test whether efficacy and safety of aquablation are non- inferior compared to HoLEP in patients with medium to large size prostates, which would clearly support the use of aquablation and change everyday clinical practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Benign Prostatic Hyperplasia (BPH)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, randomized, open-label, non-inferiority clinical trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aquablation
Arm Type
Experimental
Arm Title
HoLEP
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Aquablation
Intervention Description
By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary. Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated.
Intervention Type
Procedure
Intervention Name(s)
HoLEP
Intervention Description
This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
Primary Outcome Measure Information:
Title
International Prostate Symptoms Score (IPSS)
Description
The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
Time Frame
6 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men ≥45 years of age Patient must be a candidate for HoLEP Refractory to medical therapy or patient is not willing to consider (further) medical treatment Patient has a prostate size of at least 50 ml and not more than 150ml, measured by transrectal ultrasound (TRUS) IPSS ≥12 QoL≥3 Qmax ≤ 15 ml/s with a minimum voided volume ≥ 125 ml or patient in urinary retention Written informed consent Exclusion Criteria: Neurogenic lower urinary tract dysfunction Urethral stenosis Preinterventionally proven adenocarcinoma of the prostate Nickel allergy Not able to complete questionnaires due to cognitive or thought disorders Language skills insufficient for informed consent and / or completion of questionnaires
Facility Information:
Facility Name
Cantonal Hospital St. Gallen
City
Saint Gallen
ZIP/Postal Code
9010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gautier Müllhaupt, MD
Phone
0041714941424
Email
gautier.muellhaupt@kssg.ch

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33941632
Citation
Mullhaupt G, Gusewell S, Schmid HP, Zumstein V, Betschart P, Engeler DS, Abt D. Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial. BMJ Open. 2021 May 3;11(5):e046973. doi: 10.1136/bmjopen-2020-046973.
Results Reference
derived

Learn more about this trial

Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates

We'll reach out to this number within 24 hrs